Noven Enters Co-Promotion Agreement with Shionogi for Brisdelle™ (Paroxetine) Capsules Co-Promotion to Extend Physician Awareness of the First and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Menopa

First Page		Document Content
Date: 2014-01-13 09:33:45		Noven Enters Co-Promotion Agreement with Shionogi for Brisdelle™ (Paroxetine) Capsules Co-Promotion to Extend Physician Awareness of the First and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Menopa Add to Reading List Source URL: www.noven.com Download Document from Source Website File Size: 266,64 KB Share Document on Facebook